Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

JNJ

Johnson & Johnson

Jan 16 • 04:00PM ET

218.66

-0.91 -0.41 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM DIA IWD

Scroll to Statements

Index	DJIA, S&P 500	P/E	21.10	EPS (ttm)	10.36	Insider Own	0.12%	Shs Outstand	2.41B	Perf Week	6.98%
Market Cap	526.82B	Forward P/E	19.04	EPS next Y	11.48	Insider Trans	-7.63%	Shs Float	2.41B	Perf Month	4.47%
Enterprise Value	554.05B	PEG	2.53	EPS next Q	2.47	Inst Own	74.26%	Short Float	0.85%	Perf Quarter	13.81%
Income	25.12B	P/S	5.72	EPS this Y	8.29%	Inst Trans	0.16%	Short Ratio	2.40	Perf Half Y	33.57%
Sales	92.15B	P/B	6.64	EPS next Y	6.25%	ROA	13.54%	Short Interest	20.43M	Perf YTD	5.66%
Book/sh	32.95	P/C	28.38	EPS next 5Y	7.52%	ROE	33.62%	52W High	219.75 -0.50%	Perf Year	50.83%
Cash/sh	7.70	P/FCF	26.88	EPS past 3/5Y	-9.49% 0.55%	ROIC	21.16%	52W Low	141.50 54.53%	Perf 3Y	25.03%
Dividend Est.	5.18 (2.37%)	EV/EBITDA	17.79	Sales past 3/5Y	-1.79% 1.58%	Gross Margin	68.27%	Volatility	2.10% 1.54%	Perf 5Y	37.20%
Dividend TTM	5.14 (2.35%)	EV/Sales	6.01	EPS Y/Y TTM	71.07%	Oper. Margin	25.79%	ATR (14)	3.60	Perf 10Y	122.76%
Dividend Ex-Date	Feb 24, 2026	Quick Ratio	0.80	Sales Y/Y TTM	5.08%	Profit Margin	27.26%	RSI (14)	69.26	Recom	2.11
Dividend Gr. 3/5Y	5.43% 5.54%	Current Ratio	1.07	EPS Q/Q	91.19%	SMA20	4.65%	Beta	0.34	Target Price	217.73
Payout	84.80%	Debt/Eq	0.58	Sales Q/Q	6.77%	SMA50	6.91%	Rel Volume	1.14	Prev Close	219.57
Employees	139800	LT Debt/Eq	0.50	Earnings	Jan 21 BMO	SMA200	23.84%	Avg Volume	8.50M	Price	218.66
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.54% 1.00%	Trades		Volume	9,698,596	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$230
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform	$203
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$206
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175

Show Previous Ratings

Today 02:00PM	Netflix, United Airlines, GE Aerospace, Intel, CPE, and More to Watch This Week (Barrons.com)
01:00PM	Trump Speech, Earnings and Other Key Things to Watch this Week (Barchart)
12:48PM	Jim Cramer Says: "J&J Deserves to Be Going Higher, But Not at This Speed, Not at This Pace" (Insider Monkey)
07:30AM	Trump in Davos, Netflix and Intel results on deck earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps: What to watch this week (Yahoo Finance)
05:00AM	Loading…
05:00AM	What to Expect in Markets This Week: Trump Davos Speech, MLK Holiday,PCE Inflation, Netflix, Intel Earnings (Investopedia)
Jan-16-26 07:00PM	Trump at Davos, Netflix earnings, SCOTUS hearing: What to Watch (Yahoo Finance Video)
04:41PM	Earnings live: PNC rounds out bank earnings this week as attention shifts to Netflix, Intel (Yahoo Finance)
03:30PM	Leaders Head to Davos, Earnings Heat Up: What to Watch Next Week (The Wall Street Journal)
03:19PM	3 Key Earnings Releases to Watch Next Week (Zacks)
02:17PM	Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026 (Insider Monkey)
12:43PM	J&Js Caplyta doubles remission rate in MDD patients (Pharmaceutical Technology)
11:30AM	Earnings Data Deluge (Zacks)
10:28AM	Pre-Markets Lower on Bank Earnings, Ahead of Bigger Week (Zacks)
Jan-15-26 12:36PM	Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients (Benzinga)
10:23AM	Loading…
10:23AM	Cramer's Mad Dash: Johnson & Johnson (CNBC TV)
09:46AM	Bayer Stock Jumps on Nubeqa Outlook, Presents Pharma Strategy (Zacks)
09:28AM	$1.5 Million at 60 Looks Solid Until You Calculate Five Years Without Medicare (24/7 Wall St.)
09:15AM	Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Jan-14-26 07:30PM	2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income (Barchart)
04:30PM	TECVAYLI monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide (PR Newswire)
12:06PM	Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio? (Zacks)
10:00AM	Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:00AM	Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know (Zacks)
Jan-13-26 11:42AM	JPM26: J&J leans on immunology launches to fuel annual growth (Pharmaceutical Technology)
11:12AM	JPM26: J&J reveals oncology strategy (Pharmaceutical Technology)
10:24AM	Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case (Benzinga)
09:45AM	Here's What Lifted Johnson & Johnson (JNJ) in Q4 (Insider Monkey)
08:09AM	AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines (Benzinga)
08:00AM	Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting (PR Newswire)
07:54AM	Loading…
07:54AM	Inside Pfizer's Oncology Performance Ahead of Q4 Results (Zacks)
07:48AM	What's Powering J&J's MedTech Growth Ahead of Q4 Release? (Zacks)
06:27AM	J&J adds 2 US manufacturing plants to investment plans (Manufacturing Dive)
05:35AM	2 No-Brainer Dividend Stocks to Buy Right Now (Motley Fool)
05:24AM	AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs. (Barrons.com)
Jan-12-26 05:45PM	Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
01:01PM	What $6,500 a Month Really Looks Like in Retirement at 67 (24/7 Wall St.)
12:49PM	How Much Monthly Income Does a $2 Million Portfolio Produce at Age 60? (24/7 Wall St.)
12:48PM	Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial (Benzinga)
11:38AM	'Biotech Super Bowl' Lands With a Thud. Stocks Slide on Lack of Deal News. (Barrons.com)
Jan-11-26 11:03AM	This ETF Is Proof That the Healthcare Rebound Is Real (MarketBeat)
Jan-10-26 10:00AM	RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer (PR Newswire)
08:59AM	The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth (24/7 Wall St.)
Jan-09-26 01:49PM	Stocks to Watch Friday: Intel, GM, Ford (The Wall Street Journal)
01:49PM	Stocks to Watch Friday Recap: Intel, GM, Ford (The Wall Street Journal)
12:49PM	J&J Finds Middle Ground in Washington (GuruFocus.com)
12:05PM	2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio (Motley Fool)
10:51AM	J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve (Zacks)
10:20AM	Cramer's Mad Dash: Johnson & Johnson (CNBC TV)
09:17AM	Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress (Zacks)
09:16AM	Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries? (Zacks)
07:44AM	Here's What We Expect From AbbVie's Immunology Segment in Q4 (Zacks)
07:28AM	HSBC lists 11 potential U.S. outperformers heading into earnings (Investing.com)
07:23AM	J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts (Pharmaceutical Technology)
06:55AM	Earnings Preview: What to Expect From Kenvues Report (Barchart)
05:23AM	The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda (Zacks)
05:10AM	Johnson & Johnson Strikes Deal With White House to Lower Drug Prices (Barrons.com)
03:27AM	Johnson & Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts (Benzinga)
Jan-08-26 09:33PM	Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices (The Wall Street Journal)
08:44PM	Johnson & Johnson reaches deal with US government to lower drug prices (Reuters)
08:24PM	Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments (Business Wire)
04:53PM	Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm (Zacks)
03:40PM	The Dividend Aristocrats No Ones Talking About (And Their 30+ Year Track Records) (24/7 Wall St.)
08:57AM	J&J's Innovative Medicine Segment in Q4: Here's What to Watch (Zacks)
07:45AM	Jim Cramer on Johnson & Johnson: "I Think It's a Terrific Entry Point" (Insider Monkey)
Jan-07-26 03:33PM	Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs (Insider Monkey)
02:16PM	Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio (Business Wire)
12:42PM	J&Js Imaavy posts win in Phase II SLE trial (Clinical Trials Arena)
11:49AM	JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus (Zacks)
11:35AM	Should You Chase the Rally in Alumis Stock Today? (Barchart)
11:34AM	The Dow Is Cruising Past Milestones. What Comes After 50,000. (Barrons.com)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:33AM	Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline (Zacks)
08:00AM	Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration (Business Wire)
03:55AM	The Smartest Dividend Stocks to Buy With $3,000 Right Now (Motley Fool)
Jan-06-26 11:51AM	JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors? (Zacks)
08:47AM	Alumis Stock Catapults More Than 100% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
05:30AM	Big Pharma Has More Going for It Than Obesity Drugs (The Wall Street Journal)
04:40AM	The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson (Zacks)
Jan-05-26 05:45PM	Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
04:19PM	Psychedelics-Tied GH Skyrockets On FDA Go-Ahead For Depression Drug (Investor's Business Daily)
03:08PM	Stock Market Today: Dow Surges As Maduro Makes This Plea; Energy Stock, Reddit Test Entries (Live Coverage) (Investor's Business Daily)
02:38PM	Flu Season's Here-This Dividend-Payer Controls the Shot Market (MarketBeat)
02:07PM	Stock Market Today: Dow Up 800 Points As Maduro Makes This Plea; Reddit Tests Entry (Live Coverage) (Investor's Business Daily)
10:38AM	3 High-Yielding Dividend Kings to Buy in January for Safe Passive Income in 2026 and Beyond (Motley Fool)
09:12AM	5 Best Passive Income Dividend Kings With Yields Up to 7% to Buy in 2026 (24/7 Wall St.)
07:41AM	Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 (Zacks)
03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Jan-03-26 09:35AM	2 Healthcare Stocks to Buy in a Bear Market (Motley Fool)
05:50AM	Dividend Growers: 3 Stocks That Could Be Worth $1 Million in 36 Years. (Motley Fool)
Jan-02-26 09:51AM	Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China (Zacks)
08:00AM	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026 (Business Wire)
07:44AM	Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth (Zacks)
Jan-01-26 08:43AM	Want Decades of Passive Income? 2 Stocks to Buy Right Now (Motley Fool)
Dec-31-25 02:41PM	Dogs of the Dow Had a Strong Year. Here Are the 10 Stocks for 2026. (Barrons.com)
09:34AM	Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs (GuruFocus.com)
09:30AM	Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It? (Zacks)
09:00AM	Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock (Zacks)
08:10AM	BAYRY's 2025 Revival: Will the Momentum Continue in 2026? (Zacks)
07:21AM	How Is Boston Scientific's Cardiovascular Growth Path Shaping Up? (Zacks)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MORIKIS JOHN G	Director	Nov 26 '25	Buy	206.15	1,250	257,688	1,849	Dec 01 04:15 PM
JOHNSON & JOHNSON	10% Owner	Nov 26 '25	Sale	10.03	6,337	63,560	4,040,861	Dec 01 04:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 24 '25	Sale	10.06	2,200	22,132	4,047,198	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 21 '25	Sale	10.00	500	5,000	4,049,398	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 06 '25	Sale	10.21	52,332	534,310	4,051,098	Nov 10 03:28 PM
JOHNSON & JOHNSON	10% Owner	Nov 07 '25	Sale	10.00	200	2,000	4,050,898	Nov 10 03:28 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Option Exercise	157.92	21,721	3,430,180	32,379	Oct 20 07:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Sale	192.71	21,721	4,185,793	10,658	Oct 20 07:13 PM
REED JOHN C	Officer	Oct 17 '25	Proposed Sale	192.71	21,721	4,185,794		Oct 17 10:23 AM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Option Exercise	101.87	56,471	5,752,701	234,484	Sep 05 06:00 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Sale	177.81	56,471	10,040,883	178,013	Sep 05 06:00 PM
Taubert Jennifer L	Officer	Sep 04 '25	Proposed Sale	177.81	56,471	10,040,904		Sep 04 02:37 PM
Forminard Elizabeth	Executive VP, General Counsel	Aug 29 '25	Option Exercise	115.67	11,521	1,332,634	22,423	Sep 03 05:13 PM
Forminard Elizabeth	Officer	Aug 29 '25	Proposed Sale	177.20	9,570	1,695,806		Aug 29 03:36 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Option Exercise	101.87	125,824	12,817,691	401,791	Aug 25 07:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Sale	179.21	125,824	22,548,655	275,967	Aug 25 07:12 PM
Duato Joaquin	Officer	Aug 22 '25	Proposed Sale	180.03	125,824	22,652,724		Aug 22 01:58 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Option Exercise	101.87	16,820	1,713,453	30,820	Aug 18 06:19 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Sale	176.91	16,820	2,975,571	14,000	Aug 18 06:19 PM
Wolk Joseph J	Officer	Aug 15 '25	Proposed Sale	176.91	16,820	2,975,571		Aug 15 03:57 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Jul 17 '25	Sale	163.55	19,137	3,129,830	10,658	Jul 18 04:12 PM
REED JOHN C	Officer	Jul 17 '25	Proposed Sale	163.55	19,137	3,129,831		Jul 17 04:05 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience